Summary
Abbott Laboratories (ABT) has filed an 8-K report on January 25, 2023, to announce its fourth quarter and full year 2022 financial results. The filing primarily includes a press release containing these results. Investors should note that Abbott, like many companies, utilizes non-GAAP financial measures to provide a clearer view of ongoing operational performance, excluding items such as acquisition-related expenses, restructuring costs, voluntary recalls, certain litigation, and tax adjustments. While these non-GAAP measures aim to offer better insight into the core business performance as assessed by management, investors are reminded to consider these alongside the Generally Accepted Accounting Principles (GAAP) measures. The press release itself, furnished as an exhibit, contains the detailed financial performance data for the periods ending December 31, 2022. Investors seeking specific figures on revenue, earnings, and segment performance should refer to this press release.
Key Highlights
- 1Abbott Laboratories announced Q4 and full-year 2022 financial results via an 8-K filing on January 25, 2023.
- 2The primary disclosure is a press release containing the detailed financial results for the specified periods.
- 3The company utilizes non-GAAP financial measures to present results, excluding items like acquisition costs, restructuring, recalls, litigation, and tax adjustments.
- 4Non-GAAP measures are presented to offer greater visibility into ongoing business performance, as assessed by management.
- 5Investors are advised to consider non-GAAP measures in conjunction with, and not as a substitute for, GAAP financial measures.
- 6The filing includes the press release as Exhibit 99.1 and the cover page data in XBRL format as Exhibit 104.